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Take home Message
Defective phagocytosis in COPD macrophages is worsened by oxidative stress and is linked 
to altered mitcohondiral function. 
 Abstract      
Background: Increased reactive oxygen species (ROS) have been implicated in the 
pathophysiology of chronic obstructive pulmonary disease (COPD).  
Objective: This study examined the effect of exogenous and endogenous oxidative stress on 
macrophage phagocytosis in patients with COPD.  
Methods: Monocyte-derived macrophages (MDM) were generated from non-smoker, 
smoker and COPD subjects, differentiated in either GM-CSF (G-Mϕ) or M-CSF (M-Mϕ). 
Alveolar macrophages were isolated from lung tissue or bronchoalveolar lavage. 
Macrophages were incubated +/- 200M H2O2 for 24 hours, then exposed to fluorescently-
labelled H. influenzae or S. pneumoniae for 4 hours, after which phagocytosis, mitochondrial 
ROS (mROS), and mitochondrial membrane potential (m) were measured.  
Results: Phagocytosis of bacteria was significantly decreased in both G-Mϕ and M-Mϕ from  
COPD patients, compared to non-smoker controls. In non-smokers and smokers, bacterial 
phagocytosis did not alter mROS or m, however in COPD, phagocytosis increased early 
mROS and decreased m in both G-Mϕ and M-Mϕ. Exogenous oxidative stress reduced 
phagocytosis in non-smoker and COPD alveolar macrophages, and non-smoker MDM, 
associated with reduced mROS production.  
Conclusion: COPD macrophages show defective phagocytosis, which is associated with 
altered mitochondrial  function and an inability to regulate mROS production. Targeting 
mitochondrial dysfunction may restore the phagocytic defect in COPD.  
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Abbreviations 
COPD – Chronic obstructive pulmonary disease 
GM-CSF – Granulocyte macrophage colony stimulating factor 
M-CSF – Macrophage colony stimulating factor 
G-Mϕ- GM-CSF differentiated macrophage 
M-Mϕ- M-CSF differentiated macrophage 
mROS – Mitochondrial reactive oxygen species 
m – Mitochondrial membrane potential  
 Introduction 
Chronic obstructive pulmonary disease (COPD) comprises three pathological conditions, 
namely emphysema, chronic bronchitis, and small airways disease [1]. COPD is 
characterized by a progressive decline in lung function which can be worsened by 
exacerbations leading to hospital admissions, morbidity and mortality [2-4]. In more 
developed nations, cigarette smoking induces inflammation and increased oxidative stress 
in the lungs, and is a major contributor to disease pathophysiology [5].  
The lung microbiome in COPD patients is altered compared to healthy individuals, 
with colonisation of the lower respiratory tract with disease specific microorganisms, 
including Haemophilus influenzae and Streptococcus pneumoniae [6]. These bacteria, 
together with viruses and other microorganisms, may drive exacerbations of COPD, which 
are associated with accelerated disease progression and worse clinical prognosis [2].  
Alveolar macrophages contribute 90–95% of cells found in bronchoalveolar lavage 
fluid and are highly phagocytic. Their main function is the removal of pathogens including 
microorganisms and apoptotic cells via phagocytosis and the regulation of inflammation [7]. 
However, in COPD, alveolar macrophages are defective at phagocytosis of bacteria, fungal 
spores, and apoptotic epithelial cells [8-10]. Monocyte-derived macrophages (MDM) are 
used as a model of alveolar macrophages, and also carry the defect in phagocytosis 
observed in COPD [11]. Different macrophage phenotypes can be generated by incubating 
monocytes with specific growth factors, to represent the heterogeneous populations of 
macrophages found in tissue including  the lungs. Granulocyte macrophage-colony 
stimulating factor (GM-CSF) and macrophage-colony stimulating factor (M-CSF) have been 
used to generate macrophage phenotypes with differing inflammatory profiles and as such 
provide a useful model for the study of macrophages phenotypes in COPD [11, 12]. There is 
increasing evidence that from in vivo models, while tissue resident macrophages play a key 
role in lung immunity, during inflammation monocytes are recruited to the lungs, which 
differentiate into macrophages to increase the macrophage pool [13, 14]. There is a 20-fold 
increase in macrophage numbers in the lungs of COPD patients with severe emphysema 
[15], and increased numbers in bronchoalveolar lavage and sputum of patients with less 
severe disease [16] indicating that monocyte recruitment is a potential source of 
macrophages in the lung during disease and that the study of MDM is relevant in COPD. 
 Mitochondria function as cellular powerhouses, producing ATP via the electron 
transport chain, and are also important in intracellular calcium regulation, apoptosis, and 
controlling the innate immune system [17]. Exposure of macrophages to cellular stress, such 
a cigarette smoke, biomass fuels or pollution, alters their mitochondrial function [18]. In 
COPD, mitochondria have been shown to be dysfunctional in airway smooth muscle cells 
[19, 20] and skeletal muscle [21, 22]. The mitochondria in these tissues showed excessive 
mROS production, which are normally counteracted by antioxidants and enzymes [23, 24]. 
It is possible that the defects seen in macrophage phagocytosis in COPD could be 
exacerbated by exogenous oxidative stress such as cigarette smoke and reactive oxygen 
species, and lead to defective mitochondrial function, as observed in airway smooth muscle 
cells from these patients [19]. We therefore studied the effects of exogenous oxidative 
stress on phagocytosis and mitochondrial function, using both GM-CSF and M-CSF 
differentiated MDM and lung derived macrophages from COPD patients in comparison with 
cells from age-matched healthy non-smokers and smokers without COPD, to determine 
whether mitochondrial dysfunction is associated with defective phagocytosis.  
  
 Methods 
Subject selection 
COPD patients were recruited from the UK Medical Research Council (MRC) COPD-MAP 
consortium of GOLD II/III patients. Control subjects included healthy non-smokers and 
smokers without COPD after screening. All subjects gave written informed consent prior to 
the start of the study and the study was approved by London-Hampstead National Research 
Ethics Committee (13/LO/1403) and the London-Chelsea National Research Ethics 
Committee (09/H0801/85). Subject demographics are presented in Tables 1-3. There was no 
difference in smoking history between smokers and COPD patients. Data on whether 
patients were current or ex-smokers was not available for this study. COPD patients had 
significantly worse lung function compared to controls. Patients continued to take their 
maintenance therapy including long-acting anti-muscarinic agents, long-acting β2-adrenergic 
agonists and inhaled corticosteroids.  
 
Macrophage isolation 
Monocyte-derived macrophages (MDM) were generated from monocytes isolated from 
peripheral blood mononuclear cells using a Percoll gradient and adherence technique, 
followed by culture in 2 ng/ml GM-CSF (Cat No. 7954-GM-059/CF, Bio-Techne, Abingdon, 
UK) to generate G-M, or 100ng/ml M-CSF to generate M-M (Cat No. 216-MC-500, Bio-
Techne, Abingdon, UK) for 12 days to generate MDM as described previously [11]. All the 
MDM used in this study were derived from freshly isolated monocytes. Macrophages were 
seeded at 0.5x106 cells/well in a 24 well plate. Alveolar macrophages were isolated from 
bronchoalveolar lavage, as described previously [25]. Lung tissue macrophages were 
isolated from lung parenchyma as described previously [26]. Lung tissue used in this study 
was assessed as being non-cancerous by the hpathologist and obtained from samples during 
tissue resection for lung cancer or emphysema.  
 
Bacteria  
Serotype 14 S. pneumoniae (NCTC 11902, National Collection of Type Cultures) was grown 
as previously described [27]. Non-typeable H. influenzae (NCTC 1269, National Collection of 
Type Cultures) was cultured on chocolate agar overnight and then grown to OD 0.6 in brain 
heart infusion (BHI) (Cat No.  CM1135, Oxoid Ltd, Basingstoke, UK) supplemented with 20% 
 (v/v) foetal calf serum (FCS) (Cat No. FB-1001/500, Biosera, Heathfield, UK), 20 μg/ml NAD 
(Cat No. NAD-100RO, Sigma-Aldrich Company Ltd, Dorset, UK ) and 10 μg/ml heme (Cat No. 
H9039, Sigma-Aldrich Company Ltd, Dorset, UK). Bacteria were not opsonized. Heat-killed 
bacteria were generated by incubation at 65 °C for 10 min as described previously [25]. 
 
Fluorescent labelling of heated killed bacteria 
Bacterial cultures were fluorescently labelled using AlexaFluor 405 NHS ester (Cat No. 
A30000, Life Technologies, Paisley, UK), or AlexaFluor 488 NHS ester (1mg/ml in DMSO, Cat 
No. A20100, Life Technologies, Paisley, UK) and incubated overnight. Labelled bacteria were 
washed repeatedly in PBS to remove unbound label, resuspended in PBS and stored at -
20°C.  
 
Bacterial phagocytosis 
Fluorescent bacterial stocks were sonicated and added to macrophages at 1.5x1010 CFU/ml 
for H. influenzae, and 1.7x108 CFU/ml for S. pneumoniae, and incubated at 37°C for 4 h. For 
flow cytometry, cells were washed with PBS to remove free bacteria, and cells dissociated 
from the plate using cell dissociation media and vigorous pipetting. Cells were transferred to 
FACS tubes, centrifuged, resuspended in 200µl PBS, and analysed by flow cytometry using a 
BD FACS Canto II, in the pacific blue channel. Data was acquired using FACS DIVA software 
and subsequently analysed using Flowjo software (Treestar, USA). For plate reader assays, 
cells were washed with PBS and fluorescence of extracellular particles was quenched by 
adding Trypan blue (2% w/v) for 1 min. Excess fluid was removed and fluorescence 
determined using an excitation at λ 480 nm and emission λ 520 nm. The relative amount of 
bacteria phagocytosed is reported as relative fluorescent units (RFU). 
 
Measurement of mROS using Mitosox assay 
Post-phagocytosis, wells were washed with Hanks’ balanced salt solution (HBSS (calcium 
free)), and 5µM mitosox dye (Cat No. M36008, Thermo Fisher, Loughborough, UK) added at 
as per manufacturer’s instructions. Cells were incubated for 30 min at 37°C, then washed 
with HBSS containing calcium (0.185g/L). Cells were dissociated from the plate using cell 
dissociation media and vigorous pipetting. Cells were transferred to FACS tubes, 
 centrifuged, and resuspended in 200µl HBSS, and analysed by flow cytometry using a BD 
FACS Canto II, in the PE channel, and bacteria were measured in the pacific blue channel.  
 
Measurement of mitochondrial membrane potential (m) using JC-1  
Post phagocytosis, JC-1 assay was performed as per manufacturer’s instructions (Cat No.  
M43152, Thermo Fisher, Loughborough, UK). Briefly, cells in a 24 well plate were washed 
with PBS and replaced with 500μl warm cell culture media. 50μM carbonyl cyanide m-
chlorophenyl hydrazone (CCCP) was added to the positive control well, and plate incubated 
for 5 min at 37°C. 2µM JC-1 dye was then added to all wells for a further 25 min at 37°C, 
after which the cells were washed with PBS. Cells were dissociated from the plate using cell 
dissociation media and vigorous pipetting. Cells were transferred to FACS tubes, 
centrifuged, and resuspended in 200µl PBS, and analysed by flow cytometry using a BD FACS 
Canto II, in the PE and FITC channel, and bacteria were measured in the pacific blue channel.  
 
Confocal Microscopy 
MDM were cultured on Ibidi μ chamber slides, and phagocytosis performed. Cells were fixed 
with 4% v/v paraformaldehyde. Nuclei were stained with DAPI (4’,6-diamidino-2-
phenylindole) and cytoplasm with cell tracker red. Slides were imaged on a Zeiss LSM-510 
inverted confocal microscope, and analysed using FIJI software.  
 
Cell viability 
Cell viability was measured by incubating MDM in 0.1% (w/v) 3-(4,5-Dimethylthiazol-2-yl)-
2,5 diphenyltetrazolium bromide (MTT) at 37°C for 30 min before removing MTT and adding  
of DMSO to lyse the cells. Absorbance was measured at λ570nm using a Spectramax 
photometer to quantify cell viability. Each treated well was normalised to the average of the 
non-treated control which was set to 100% viability. 
 
Statistical analysis 
Data are presented as mean ± SEM or as individual data points, and significance analysed 
using either a Wilcoxon matched pairs signed rank test for comparison of two variables, or 
Kruskal Wallis test for comparison of multiple variables with post hoc Dunn’s test using 
GraphPad Prism 5 software (GraphPad, USA).  
 Results 
Correlation between phagocytosis of alveolar macrophages and MDM 
In order to further validate the use of MDM to assess phagocytic capacitiy of macropahges, 
alveolar macrophages and MDM were isolated from the same patient, and phagocytic 
assays performed. Significant correlations were observed in the phagocytic capacity of 
alveolar macrophages and either M-Mϕ or G-Mϕ for both H. influenzae (r=0.63 and 0.71 
respectivly, Figure 1A, B), and S. pneumoniae (r=0.40 and 0.60 respectivly, Figure 1C, D). 
Internalisation of bacteria was confirmed by confocal microscopy (Fig. 1E-G). From these 
data, the MDM model was used in future experiments, where alveolar macrophages were 
not available.  
 
Defective macrophage phagocytosis in COPD 
Experiments were performed in order to confirm previous data showing defective 
phagocytosis by COPD macrophages.  Regardless whether MDM were differentiated with 
GM-CSF or M-CSF, there was a significant reduction in uptake of both H. influenzae and S. 
pneumoniae by COPD macrophages in comparison to healthy volunteer derived cells 
(p<0.05), measured by MFI (Fig. 2B and 2D).  However, irrespective of subject group, 60-80% 
of cells were capable of phagocytosis, measured by % macrophage phagocytosis (Fig. 2A and 
2C). In addition, there were no differences between the ability of G-Mϕ and M-Mϕ to 
phagocytose, although M-Mϕ displayed a trend for increased phagocytosis compared with 
G-Mϕ from all subject groups.  
 
Exogenous oxidative stress on macrophage phagocytosis 
Alveolar macrophages and MDM were exposed to 200μM H2O2 for 24h, and phagocytosis 
measured by median fluorescence intensity (MFI). Pilot studies showed that 200µM H2O2 
was the maximal concentration to have no effect on cell viability (Supplementary Figure 1). 
Exposure of alveolar macrophages to H2O2 decreased phagocytosis of H. influenzae (NS 
p<0.05, COPD p<0.05, Fig 3A) and S. pneumoniae (NS p<0.05, COPD p<0.05, Fig. 3B) in cells 
from non-smokers and COPD patients. Exposure of non-smoker G-Mϕ and M-Mϕ to H2O2 
decreased phagocytosis of H. influenzae (p<0.05, Fig 3C, E) and S. pneumoniae (p<0.05, Fig. 
3D, F), while exposure of COPD M-Mϕ and G-Mϕ decreased phagocytosis of S. pneumoniae 
(p<0.05, Fig. 3D, F), but not H. influenzae (p>0.05, Fig 3C, E, F). 
  
Macrophage mitochondrial reactive oxygen species in response to phagocytosis 
At baseline, mROS levels were similar in all cells from all subject groups irrespective of the 
differentiation process (Table 4). Similarly phagocytosis of either H. influenzae or S. 
pneumoniae had no effect on mROS levels in either G-Mϕ and M-Mϕ  from non-smokers 
(Fig. 4A and B) or smokers without COPD (Fig. 4C and D), However, in COPD M-Mϕ, 
phagocytosis of both H. influenzae and S. pneumoniae led to a significant increase in mROS 
levels of 58% (p<0.01) and  59% (p<0.05) respectively (Fig 4E). In contrast, only phagocytosis 
of H. influenzae (50%, p<0.05) but not S. pneumoniae increased mROS levels in COPD G-Mϕ 
(Fig. 4F).  
We next measured m to determine whether this observation could be due to 
changes in mitochondrial function. At baseline, there was no difference in m between 
patient groups, or macrophage phenotypes (Table 4). After phagocytosis, there was no 
change in  m  in both G-Mϕ and M-Mϕ from non-smokers and smokers without COPD 
(Fig. 5A-D). In contrast, phagocytosis of H. influenzae, but not S. pneumoniae caused a 
significant decrease in m in both G-M (p<0.05, Fig. 5D) and M-M (p<0.05, Fig 5D) from 
COPD patients. The positive control CCCP reduced m in all cell types (p<0.001, Fig 5). 
 
Exogenous oxidative stress and mitochondrial function 
Having shown that exogenous oxidative stress impairs phagocytosis in cells from non-
smokers and COPD patients, the effect on mitochondrial function was also investigated. At 
baseline, H2O2 had no effect on mROS or m in any cell type from any of the subjects used 
in this study (Table 4). However, after phagocytosis, changes were observed. In M-M, non-
smoker cells that had been exposed to H2O2 showed a decrease in mROS after phagocytosis 
of both H. influenzae (p<0.05, Fig 6 A) and S. pneumoniae (p<0.05, Fig 6B), while in COPD a 
decrease was also seen with both bacterial species (p<0.01, Fig 6A and B). In G-M, non-
smoker cells that had been exposed to H2O2 showed a decrease in mROS after phagocytosis 
of both H. influenzae (p<0.05, Fig 6C) and S. pneumoniae (p<0.05, Fig 6D), while in smokers 
without COPD a decrease was also seen with both bacterial species (p<0.05, Fig 6C, D). In 
COPD G-M,  decrease was seen with S. pneumoniae (p<0.05, Fig 6D) but did not reach 
 significance in cells exposed to H. influenzae (p=0.054). No effect of H2O2 and phagocytosis 
was seen on m in any cell type studied (p>0.05, Fig 7).  
Discussion 
Alveolar macrophages are phagocytic cells that patrol the airways and removed inhaled 
particulates and microorganisms [28]. However, COPD macrophages phagocytose bacteria 
poorly, which could contribute to bacterial colonisation of the lungs, and lead to worsening 
of symptoms and lung function decline [8, 11]. MDM have been shown to be an effective 
model of alveolar macrophages, as they share the functional defect in phagocytosis and are 
more easily obtainable than alveolar macrophages [11]. In this study, we generated MDM 
by differentiating monocytes in GM-CSF (G-Mϕ) or M-CSF (M-Mϕ) to investigate two 
macrophage phenotypes that have been characterised by others previously [29-31], and 
confirmed key data using alveolar macrophages isolated from lung tissue [32].  
 In the present study, we have demonstrated that in both G-Mϕ and M-Mϕ 
phenotypes, there was a significant decrease in phagocytosis of the respiratory pathogens, 
H. influenzae (p<0.05) and S. pneumoniae (p<0.05), by COPD macrophages compared to 
non-smoker macrophages. However, there was no difference in the percentage of 
macrophages from healthy subjects or COPD patients that were able to phagocytose. These 
data suggest that while all macrophages are able to undergo the process of phagocytosis, it 
is the amount of bacteria, as measured by MFI, that can be consumed that is reduced in 
COPD. Importantly, there was no significant decrease in phagocytosis in smoker 
macrophages compared to non-smokers, although there was a trend to decrease 
phagocytosis of H. influenzae with G-Mϕ (p=0.08), indicating that it is the disease rather 
then smoking history that determines this defect. These data confirm our previous 
observations [11], but we now show that differentiation of macrophages in M-CSF also leads 
to an aberrant macrophage phenotype in COPD suggesting that this effect is not due to 
culture conditions alone but is potentially inherent in monocyte precursors. Therefore, this 
systemic defect further contributes to the reduced clearance of bacterial pathogens by 
macrophages in the lungs and may account for increased bacterial colonisation and the 
concomitant decline in lung function observed in COPD. In addition, the increased rates of 
pneumococcal bacteraemia in COPD may also be influenced by impaired function of blood 
monocytes and splenic macrophages [33]. Potential roles for defective circulating monocyte 
function in COPD co-morbidities could be an area for future study. 
 In more developed nations, most COPD cases are due to cigarette smoking, which 
introduces high levels of oxidative stress into the lungs [34] could be a contributing factor to 
the decreased function of COPD macrophages. To test this, we applied exogenous oxidative 
stress in the form of H2O2, to macrophages at a physiologically relevant concentration for 
24h [35]. H2O2 is released from activated inflammatory and structural cells, and is a 
component of cigarette smoke and air pollution [36]. We showed that exogenous oxidative 
stress caused a reduction in phagocytosis in both healthy and COPD alveolar macrophages 
and in both G-Mϕ and M-Mϕ from non-smokers, indicating that exposure to high levels of 
oxidative stress in the lungs could be a factor that influences defective macrophage 
phagocytosis in COPD. Interestingly, MDM from smokers without COPD did not respond to 
exogenous oxidative stress, which could indicate a protective mechanism within smoker 
cells, such as increased expression of anti-oxidants. This is important as we have already 
demonstrated the role of Nrf2 in COPD [37].  
We studied this further, and showed that macrophages cultured in the absence of 
exogenous oxidative stress showed no baseline differences in mROS or m between 
patient groups at the early time point studied. However, when the cells were analysed after 
phagocytosis of H.influenzae, both COPD MDM phenotypes showed increased levels of 
mROS and reduced m, whereas macrophages from control subjects had no change 
compared to baseline. After phagocytosis of S.pneumoniae, there was a similar increase in 
mROS levels in M-Mϕ, but not in G-Mϕ from COPD patients, and there was no change in 
m, indicating a differential response to bacterial species. One caveat with these data, is 
that extracellular fluorescence could not be quenched and therefore there maybe some 
contribution of extracellular bacteria to the response. Nevertheless, the differential 
responses from the different macrophage phenotypes may reflect alternative mechanisms 
for deriving ATP. It is known that M1 macrophages ulitize a glycolytic pathway whereas M2 
macrophages utilise oxidative phosphorylation [38], an effect mirrored by G-Mϕ and M- Mϕ 
respectively [39].  
ROS induces damage by oxidising proteins and DNA, including mitochondrial DNA 
[40]. mROS released from mitochondria that are adjacent to phagolysosomes containing 
bacteria has been shown to be bactericidal in macrophages [41] and, so increasing the early 
production of mROS post phagocytosis, may be a mechanism by which macrophages clear 
bacteria [42]. However, this increase in mROS will then be scavenged by intracellular 
 enzymes including superoxide dismutase, to prevent damage to the cell [17]. The lack of a 
difference in mROS levels post-phagocytosis in macrophages from healthy subjects suggests 
that if mROS are induced to assist in bacterial clearance, these oxidative species are rapidly 
quenched. The continued elevation in mROS in COPD macrophages suggests that the cells 
are unable to regulate mROS production, or that excessive levels of mROS are being 
generated which may overwhelm the endogenous anti-oxidant enzymes. It has been shown 
that levels of antioxidants, such as hemeoxygenase (HO)-1 that are regulated by the 
transcription factor Nrf-2, and superoxide dismutase, are decreased in COPD macrophages, 
which could contribute to the dysregulation of mROS seen here [43, 44]. Recently, we 
demonstrated that the Nrf-2 activator, sulforophane, was able to restore both non-opsonic 
and opsonic phagocytosis of S. pneumoniae in both alveolar macrophages and MDM from 
COPD patients, further supporting the pivotal role of ROS in driving the defects in 
macrophage responsiveness to pathogens [37]. We have also identified chronic oxidative 
stress in alveolar macrophages from COPD patients [45] and our observations of intrinsic 
alterations in mitochondrial function and mROS generation in COPD MDM could result in 
the chronic oxidative stress observed in COPD alveolar macrophages in vivo. The data 
presented in the current study complements these findings in a separate cohort of subjects 
and, suggests that intrinsic mitochondrial function could drive both phagocytic defects and 
the oxidative stress that leads to this. 
Excess levels of oxidants within the cell can cause damage to cellular components 
and induce apoptosis [17]. Therefore, following phagocytosis, increased mROS in COPD 
macrophages, may alter the capacity of the cell to phagocytose subsequently, and 
contribute to the defective phagocytic pattern of ‘early satiety’ seen in COPD. Exactly why 
the mitochondria are producing excessive ROS is unclear, however this study shows a 
decreased m indicative of unhealthy mitochondria (20). Excessive elevated mROS 
generated following phagocytosis in COPD macrophages may lead to generation of pro-
inflammatory cytokines due to activation of the inflammasome,  transcription factors, and 
further to cell damage in COPD (18).  
It has previously been shown that mROS is elevated in alveolar macrophages from 
COPD patients at baseline, but not following in vitro infection with S. pneumoniae [45]. This 
differs from our findings in MDM, but may suggest that macrophages from the lungs, which 
will have already been exposed to lung bacteria, are primed to have elevated mROS, 
 whereas blood macrophages require priming by exposure to bacteria to unmask the 
intrinsic mitochondrial defect we describe, and subsequently display increased oxidative 
stress. Further analysis of mitochondrial function in alveolar and MDM is warrented to 
understand this complex processes.  
Having established that mitochondrial function is abnormal in COPD macrophages, it 
was of interest to study whether exogenous oxidative stress was acting by altering 
mitochondrial function within macrophages. mROS and m were measured in MDM pre-
treated with H2O2. At baseline H2O2 had no affect on both aspects of mitochondrial function, 
but after phagocytosis, H2O2 caused a decrease in mROS in both G-Mϕ and M-Mϕ from non-
smokers, and COPD patients. This response may be due to exogenous oxidative stress 
reducing endogenous oxidative stress through alteration of the mROS/anti-oxidant balance 
within the cell, in order to limit the damage caused, or due to damage to the mitochondria 
itself, reducing cellular function. Alterations in mitochondrial function might lead to changes 
in metabolic balance of the cell and energy generation. One possible outcome from this, 
could be changes in the phagocytic process possibly via alterations in dynamics of the 
cytoskeleton. Further, mitochondrial ROS is utilised in the killing of bacteria inside the cell, 
and so dysfunctional ROS production may alter the cells ability to function appropriately to a 
bacterial pathogen. However, targeting mitochondrial defects is difficult but is a potential 
therapeutic approach [46]. 
 In summary, both alveolar macrophages and G-Mϕ and M-Mϕ macrophage 
phenotypes from COPD patients demonstrate reduced phagocytosis of airway pathogens, 
which provides further support for the theory that there is an inherent circulating 
phagocytic defect in monocytes in disease. The reduction in phagocytosis is associated with 
dysregulation of mitochondrial function and intracellular mROS generation. Targeting 
mitochondria represents a treatment option for COPD, which may reverse the defective 
phagocytosis and lead to reduced exacerbations in this disease. 
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 Figure Legends 
Figure 1. Correlations of phagocytosis of respiratory pathogens between alveolar 
macroohages and MDM from the same subjects.  
Panels A-D - Non-smoker (n=7), smoker ( n=7) and COPD (● n=6) alveolar macrophages, 
M-Mϕ and G-Mϕ were isolated from the same subject, co-cultured with fluorescently-
labelled H. influenzae (HI, panels A and B) or S. pneumoniae (SP, panels C and D) bacteria for 
4 hours and phagocytosis measured by relative fluorescence units (RFU). Data are individual 
data points and correlation (r) is reported as Spearman’s rank coefficient.  
Panels E-F - Confocal microscopic images of samples confirm internalisation of bacteria in G-
Mϕ (Panel E) and M-Mϕ (Panel F), and in orthogonal images of a Z-stack of G-Mϕ 
macrophages (Panel G). Images show cytoplasm (cell tracker red), nucleus (blue - DAPI) and 
H. influenzae (green, Alexa-488).  
 
Figure 2 – Internalisation of bacteria by macrophages from non-smokers, smokers and 
COPD patients 
M-Mϕ and G-Mϕ from non-smokers (solid bars), smokers without COPD (vertical hatched 
bars) and COPD patients (horizontal hatched bars) were co-cultured with fluorescently-
labelled H. influenzae (HI, panels A and B) or S. pneumoniae (SP, panels C and D) bacteria for 
4 hours, after which the percentage of cells that had undergone phagocytosis (panels B and 
D) and median fluorescence intensity (MFI, panel A and C) were measured by flow 
cytometry. Data are represented as mean ± SEM of 9-12 independent experiments. *p<0.05 
non-smoker vs COPD.   
 
Figure 3 – Effect of exogenous oxidative stress decreases macrophage phagocytosis.  
Alveolar macrophages (panels A and B, healthy=13, COPD=7), M-Mϕ (panels C and D) or G-
Mϕ (panels E and F)  from non-smokers (N=12), smokers without COPD (N=8-9) and COPD 
patients (N=10-11) were left untreated, or treated with 200µM hydrogen peroxide (H202) for 
24 hours, then co-cultured with fluorescently-labelled H. influenzae (HI, panels A, C, E) or S. 
pneumoniae (SP, panels B, D, F) bacteria for 4 hours, after which median fluorescence 
intensity (MFI) of phagocytosis was measured by flow cytometry. Data are represented as 
individual data points and as mean±SEM of untreated () or H202 treated cells (). *p<0.05, 
**p<0.01, ***p<0.001 untreated vs H202.   
  
Figure 4 – Increased production of mitochondrial reactive oxygen species (mROS) in COPD 
macrophages in response to phagocytosis 
M-Mϕ (panels A, C, E) or G-Mϕ (panels B, D, F) from non-smokers (N=10, panels A-B), 
smokers without COPD (N=9-10, panels C-D) and COPD patients (N=13, panels E-F) were 
analysed for mROS levels after 4 hour co-culture with fluorescently-labelled H. influenzae 
(HI) or S. pneumoniae (SP). Data are normalised to un-treated control (UT). *p<0.01, 
**p<0.01 non-stimulated vs bacteria.  
 
Figure 5 – Decreased mitochondrial membrane potential (m) in COPD macrophages in 
response to phagocytosis. M-Mϕ (panels A, C, E) or G-Mϕ (panels B, D, F) from non-
smokers (N=10, panels A-B), smokers without COPD (N=10, Panels C-D) and COPD patients 
(N=10, panels E-F) were analysed for m after 4 hour co-culture with fluorescently-
labelled H. influenzae (HI) or S. pneumoniae (SP), with carbonyl cyanide m-chlorophenyl 
hydrazine (CCCP) acting as a positive control. Data show fold change from un-treated 
control (UT). *p<0.05, *p<0.01, ***p<0.001 vs. non-stimulated.   
 
Figure 6 – Exogenous oxidative stress decreases mitochondrial reactive oxygen species 
(mROS) production in macrophages.  
M-Mϕ (panels A-B) or G-Mϕ (panels C-D) from non-smokers (N=12), smokers without COPD 
(N=7-9) and COPD patients (N=9-11) were treated with 200µM hydrogen peroxide (H202) for 
24 hours, then co-cultured with fluorescently-labelled H. influenzae (HI, panels A and C) or S. 
pneumoniae (SP, panels B and D) bacteria for 4 hours, after which mROS was measured by 
flow cytometry. Data are represented as individual data points and as mean±SEM of 
untreated () or H202 treated cells ().  *p<0.05 untreated vs H2O2.  
 
Figure 7 – Exogenous oxidative stress does not affect mitochondrial membrane potential 
in macrophages.  
M-Mϕ (panels A-B) or G-Mϕ (panels C-D) from non-smokers (N=8), smoker (N=8-9) and 
COPD patients (N=8-11) were treated with 200µM hydrogen peroxide (H202) for 24 hours, 
then co-cultured with fluorescently-labelled H. influenzae (HI, panels A and C) or S. 
pneumoniae (SP, panels B and D) bacteria for 4 hours, after which m was measured by 
 flow cytometry. Data are represented as individual data points and as mean±SEM of 
untreated () or H202 treated cells ().  
Supplementary Figure 1 – Exogenous oxidative stress does not alter macrophage viability 
M-Mϕ (black circles, N=7) or G-Mϕ (grey squares, N=10) were treated with 1-200µM 
hydrogen peroxide (H202) for 24 hours then co-cultured with fluorescently-labelled H. 
influenzae (HI, panel A) or S. pneumoniae (SP, panel B) bacteria for 4 hours and cell viability 
measured by MTT assay. Data are pooled from non-smoker, smoker and COPD subjects, and 
show mean ± SEM.  
  
  
 
Table 1 
 Non-smoker 
n=17 
Smoker 
n=16 
COPD 
n=17 
Age 61±3 57±3 60±2 
Pack years 0 32±10* 30±3** 
FEV1(L) 3.2±0.3 2.9±0.4 1.7±0.2** 
FEV1 % predicted 109±6 92±4 68±3*** 
FVC (L) 3.7±0.3 3.7±0.4 2.7±0.3 
FEV1:FVC 0.80±0.02 0.76±0.03 0.69±0.04* 
 
Table 1 – Subject demographics for patients analysed in figure 1 . Data represented as 
mean ± SEM. *p<0.05, **p<0.01 Non-smoker vs. smoker/COPD. Chonric obstructive 
pulmonary disease (COPD), Male (M), Female (F), Forced experiatory volume in one second 
(FEV1), Litres (L), Forced vital capacity (FVC).  
 
  
  
Table 2. 
 
 Healthy 
n=13 
COPD 
n=7 
Age 62±3 68±4 
Pack years 20±5 32±4 
FEV1(L) 2.7±0.2 1.7±0.2*** 
FEV1 % predicted 94±4 70±8* 
FVC (L) 3.7±0.2 3.1±0.2 
FEV1:FVC 0.73±0.03 0.56±0.05** 
 
Table 2 – Subject demographics for lung macrophages used in Figure 3. Macrophages were 
isolated from tissue resection (n=12) or bronchialveolar lavage (n=8). Data represented as 
mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 Healthy vs. COPD. Chronic obstructive 
pulmonary disease (COPD), Male (M), Female (F), Forced experiatory volume in one second 
(FEV1), Litres (L), Forced vital capacity (FVC).  
 
  
  
 
Table 3 
 Non-smoker Smoker COPD 
Sex (M:F) 10:7 13:3 10:7 
Age 61±2 63±2 71±3 
Pack years 0 29±4*** 47±7*** 
FEV1(L) 2.9±0.3 3.0±0.2### 1.5±0.2*** 
FEV1 % predicted 100±5 94±3### 55±5*** 
FVC (L) 3.9±0.3 4.2±0.3# 2.8±0.3* 
FEV1:FVC 0.76±0.02 0.73±0.02### 0.52±0.04*** 
 
Table 3 – Subject demographics for monocyte-derived macrophages. Data represented as 
mean ± SEM. *p<0.05, ***p<0.001 Non-smoker vs. smoker/COPD. #p<0.05, ##p<0.01 
###p<0.001, smoker vs. COPD. Chonric obstructive pulmonary disease (COPD), Male (M), 
Female (F), Forced experiatory volume in one second (FEV1), Litres (L), Forced vital capacity 
(FVC).  
  
  
Table 
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Table 4 – Baseline values for mROS and  m. Data shows baseline values for untreated 
(UT) cells or cells treated with 200Μm H2O2 for 24 h. Data represented as mean±SEM. 
Chonric obstructive pulmonary disease (COPD), mitochondrial reactive oxygen species 
(mROS), mitochondrial membrane potential (m), M-CSF derived macrophages (M-Mϕ), 
GM-CSF derived macrophage (G-Mϕ).  
 
 mROS m 
M-Mϕ G-Mϕ M-Mϕ G-Mϕ 
UT H2O2 UT H2O2 UT H2O2 UT H2O2 
Non-
smoker 
2.06  
(0.4) 
1.92 
(0.4) 
2.34 
(0.4) 
2.3 
(0.4) 
1.09 
(0.06) 
1.05 
(0.09) 
1.39 
(0.09)  
1.43 
(0.15) 
Smoker 2.13 
(0.6) 
2.37 
(0.7) 
2.27 
(0.5) 
2.20 
(0.5) 
1.08 
(0.07) 
1.09 
(0.06) 
1.15 
(0.07) 
1.14 
(0.09) 
COPD 2.24  
(0.4) 
1.81 
(0.4) 
2.55 
(0.5) 
2.42 
(0.5) 
1.06 
(0.11) 
1.02 
(0.10) 
1.28 
(0.15) 
1.29 
(0.12) 
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Supplementary figure 1
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